Home・Akciju saraksts・Sanofi

Sanofi

Atvērts

43.44 1.64

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

42.74

Max

43.72

Galvenie mērījumi
By Trading Economics
Ienākumi	-1.3B 343M
Pārdošana	1.1B 12B
P/E Sektora vidējais	23.532 56.597
EPS	1.21
Dividenžu ienesīgums	9.29
Peļņas marža	2.789
Darbinieki	74,846
EBITDA	-1B 1.7B

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+30.93% upside

Dividendes
By Acuity
Dividenžu ienesīgums Sektora vidējais	9.29% 2.18%

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.2B 106B
Iepriekšējā atvēršanas cena	41.8
Iepriekšējā slēgšanas cena	43.44

Sanofi Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. sept. 23:51 UTC

Brazil's Business Confidence Index (ICEI) for September 2026 set to release on September 14, with cautious optimism amid persistent pessimism and geopolitical challenges.

2026. g. 13. sept. 23:41 UTC

GBP/AUD shows notable strength in after-market trading, reaching a cumulative return peak of 0.17% since Friday's close, with no specific news identified.

2026. g. 13. sept. 23:41 UTC

Correlated Moves

EUR/AUD is higher in after-market trading, diverging from the lower Nasdaq 100 Index amid heightened Fed interest rate hike expectations following a strong consumer price index report.

2026. g. 13. sept. 23:31 UTC

China's House Price Index YoY release on September 15, 2026, is anticipated to reveal ongoing weakness in the housing sector amid cautious optimism from recent policy measures.

2026. g. 13. sept. 23:31 UTC

U.S. Building Permits Forecasted at 1.41 Million for August Amid Stable Market Sentiment Ahead of September Release

2026. g. 13. sept. 23:31 UTC

Upcoming U.S. Housing Starts Data Release on September 17 Expected to Influence Economic Outlook Amidst Market Fluctuations.

2026. g. 13. sept. 23:31 UTC

U.S. Housing Starts Expected to Recover Slightly to 1.32 Million Units Amid Ongoing Concerns Over High Mortgage Rates and Recent Declines

2026. g. 13. sept. 23:31 UTC

Philadelphia Fed Manufacturing Index Set for Release Amid Positive Sentiment and Anticipated Growth, Forecasted at 30.0

2026. g. 13. sept. 23:31 UTC

U.S. Building Permits Data Set for Release on September 17, 2026, Amid Cautious Optimism in Housing Market Sentiment

2026. g. 13. sept. 23:31 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in August Amid Cautious Optimism on Consumer Spending

2026. g. 13. sept. 23:31 UTC

Retail Sales MoM report for August 2026 set to release on September 16, with a forecasted increase of 0.9% amid cautious consumer spending sentiment following July's unexpected decline.

2026. g. 13. sept. 23:31 UTC

U.S. Import Prices MoM data for August 2026 set to release on September 16, with a modest increase of 0.2% expected amid inflation concerns and potential Fed interest rate adjustments.

2026. g. 13. sept. 23:31 UTC

U.S. Export Prices MoM Release on September 16 Expected to Impact Monetary Policy Amidst Recent Price Decline and Mixed Market Sentiment

2026. g. 13. sept. 23:21 UTC

Macro News

News

Bitcoin is lower as U.S.-China tensions rise and crude oil prices fall. Regulatory optimism around the Bitcoin and Crypto Clarity Act fails to boost sentiment.

2026. g. 13. sept. 23:11 UTC

EUR/NZD is trading lower during after-market hours, settling at -0.11%. The currency pair remains above its 20-day moving average.

2026. g. 13. sept. 23:01 UTC

EUR/JPY trades higher in after-market hours, recovering from earlier lows amid expectations for a Federal Reserve interest rate hike on September 16.

2026. g. 13. sept. 23:01 UTC

Correlated Moves

The AUD/USD is lower during after-market hours, reflecting declines in the Nasdaq 100 Index and influenced by recent consumer price index data.

2026. g. 13. sept. 23:01 UTC

Macro News

Correlated Moves

Geopolitical tensions with China and domestic electricity concerns contribute to a decline in the Dow Jones Index, which has reached a session low below its 20-day moving average.

2026. g. 13. sept. 23:01 UTC

Macro News

Correlated Moves

U.S.-China tensions rise over arms deals with Taiwan, impacting market sentiment. The S&P 500 Index is trading lower today, reflecting broader market weakness.

2026. g. 13. sept. 23:01 UTC

Macro News

Geopolitical tensions are driving WTI prices higher as concerns about U.S.-China relations and Iranian pressures on Saudi Arabia impact global oil markets.

2026. g. 13. sept. 23:01 UTC

Correlated Moves

The Russell 2000 Index is lower today, continuing a downward trend amid broader market sentiment influenced by rising core CPI data and Fed rate hike expectations.

2026. g. 13. sept. 23:01 UTC

Correlated Moves

Platinum is trading lower, influenced by a decline in silver prices amid rising consumer inflation and expectations for a Federal Reserve interest rate hike.

2026. g. 13. sept. 23:01 UTC

EUR/SEK is trading lower during after-market hours, reflecting a slight decline since Friday's close. The asset remains near its one-month range high.

2026. g. 13. sept. 23:01 UTC

Correlated Moves

Silver prices are lower, influenced by gold's decline and inflation data. The asset remains below its 20-day moving average amid market pressures.

2026. g. 13. sept. 23:01 UTC

The Nasdaq 100 Index is lower amid ongoing market weakness, following a consumer price index report that exceeded expectations and heightened rate hike speculation.

2026. g. 13. sept. 23:01 UTC

Natural Gas is trading higher, continuing gains from Friday's close. Prices reached their highest point during the session, with no specific news identified.

2026. g. 13. sept. 23:01 UTC

EUR/CZK is trading lower in after-market hours, reflecting a modest decline since Friday's close amid solidified market expectations for a Federal Reserve interest rate hike.

2026. g. 13. sept. 23:01 UTC

Macro News

Correlated Moves

Gold prices are lower as market expectations grow for a Federal Reserve interest rate hike. Goldman Sachs anticipates a 25 basis-point increase at the FOMC meeting.

2026. g. 13. sept. 23:01 UTC

Ethereum is trading lower, continuing a downward trend since Saturday's close. The asset reached a session low earlier today.

2026. g. 13. sept. 22:51 UTC

Canada's Housing Starts Data Release on September 16 Expected to Show Continued Weakness Amid Economic Pressures

Salīdzinājums

Cenas izmaiņa

Sanofi Prognoze

Cenas mērķis

By TipRanks

30.93% augšup

Prognoze 12 mēnešiem

Vidējais 56 USD 30.93%

Augstākais 62 USD

Zemākais 49 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Sanofi — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Sanofi — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.